Abstract
The aim of this study was to investigate the early outcome of the taxotere and cisplatin chemoradiotherapy to the advanced cervical cancer. Fifty-six cases with cervical cancer (FIGO II b to IVa) were divided randomly into two groups: radiotherapy alone (28 cases) and radiation plus chemotherapy (TP) group. There was no difference of radiotherapy between the two groups. The RT+C cases who received TP regimen during the radiation, and DDP once weekly injection of vain, according to 20 mg/m2 and taxotere once weekly i.v. according to 35 mg/m2.These regimen were given for 4~5 weeks, and some medicine for vomiting was given to the RT+C cases. Two groups were received an oral medicine MA 160 mg every day during the treatment. The early outcome: the complete remission rate was 64.3% and partial remission rate was 35.7% in RT+C. the complete remission rate was 32.1% and partial remission rate was 39.3% in RT. The total response rate and complete remission of RT+C group was higher than that of the RT group. There was significant difference between the two groups. The taxotere and cisplatin chemoradiotherapy can improve the early outcome of the advanced cervical cancer, the adverse effects being endurable.
Highlights
Cervical cancer is the most common gynecologic cancer
We conclude that taxotere and cisplatin chemoradiotherapy can improve the early outcome of the advanced cervical cancer, the adverse effects being endurable
Effect of treatment According to general standard for solid tumor treatment efficacy (Sun and Zhou, 2002), the outcome of treatment divided into complete remission (CR), partial remission (PR), stable (NC) and deterioration (PD)
Summary
Cervical cancer is the most common gynecologic cancer. Surgery or radiotherapy can achieve satisfactory effect for early stage cervical cancer, while in the late stage (II b-IV a period) the main treatment therapy is radiation. Concurrent chemoradiation, using cisplatin-based chemotheraphy (either cisplatin alone or cisplatin/5fluorouracil), is the treatment of choice for stages Ib-IV a disease based on the results of 5 randomized clinical trials (Rose et al, 1999; Morris et al, 1999; Thomas, 1999; Peters et al, 2000; Green et al, 2001; Higgins et al, 2003; Lorvidhaya et al, 2003; Lu et al, 2003; Dubay et al, 2004; Eifel et al, 2004; Rose et al, 2007; Duenas-Gonzale et al, 2009). These 5 trials have shown that the use of Concurrent chemoradiation results in a 30%-50% decrease in the risk of death compared to RT alone. To investigate the early outcome of the taxotere and cisplatin chemoradiotherapy to the advanced cervical cancer 56 patients with cervical cancer in II b-IV stage, who hospitalized in oncology unit from September 2009 to October 2010, were randomly divided into chemoradiotherapy group and radiotherapy group for comparison
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call